The Journal of dermatological treatment最新文献

{"title":"Deprescribing in dermatology.","authors":"Karolina Perez, Daniel Butler","doi":"10.1080/09546634.2026.2654941","DOIUrl":"https://doi.org/10.1080/09546634.2026.2654941","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2654941"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147647999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of polyphenolic compounds for hair regeneration: a systematic review and meta-analysis of randomized controlled trials.","authors":"Chaimae El Ammari, Ana María García-Muñoz, Rubén Zapata-Pérez, Rubén Rabadán-Ros, Carmen Lucas-Abellán, Rebeca González-Louzao, Desirée Victoria-Montesinos","doi":"10.1080/09546634.2026.2654112","DOIUrl":"10.1080/09546634.2026.2654112","url":null,"abstract":"<p><strong>Background: </strong>Non-scarring alopecia, including androgenetic alopecia, alopecia areata, and telogen effluvium, is highly prevalent and often associated with significant psychosocial burden. Although treatments such as minoxidil and finasteride are available, variability in response and tolerability concerns have increased interest in alternative therapeutic approaches. Polyphenolic compounds have attracted attention due to their antioxidant, anti-inflammatory, and immunomodulatory properties.</p><p><strong>Objectives: </strong>This systematic review and meta-analysis evaluated the efficacy of oral and topical polyphenolic interventions for hair regeneration in adults with non-scarring alopecia.</p><p><strong>Methods: </strong>A systematic search of PubMed/MEDLINE, Scopus, Web of Science, and Cochrane CENTRAL was conducted according to PRISMA 2020 guidelines (PROSPERO: CRD420251230149). Randomized, blinded controlled trials were included. Primary outcomes were objective trichoscopic measures, including hair density and total area hair count.</p><p><strong>Results: </strong>Thirty-two randomized controlled trials involving 2,183 participants were analyzed. Compared with controls, polyphenolic interventions significantly improved hair density (SMD 0.90; 95% CI 0.51-1.30) and total area hair count (SMD 1.03; 95% CI 0.42-1.63), although substantial heterogeneity was observed. Direct comparisons with minoxidil did not show significant differences in overall hair count outcomes.</p><p><strong>Conclusions: </strong>Current evidence suggests that selected polyphenolic formulations may represent a potential adjunctive therapeutic approach in non-scarring alopecia, though further standardized and long-term trials are warranted.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2654112"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of combining microneedling with oral doxycycline for the treatment of rosacea: a retrospective comparative cohort study.","authors":"Kuanyu Xia, Yiran Peng, Zixi Jiang, Yaling Wang, Wei Shi, Mengting Chen, Guo Li, Zhixiang Zhao, Dan Jian","doi":"10.1080/09546634.2026.2665538","DOIUrl":"10.1080/09546634.2026.2665538","url":null,"abstract":"<p><strong>Purpose/aim of the study: </strong>Oral doxycycline (DOX) is a first-line systemic therapy for rosacea; however, persistent vascular features, such as fixed erythema and flushing, and neurosensory symptoms, such as burning, may respond incompletely to DOX alone. This study aimed to evaluate whether adding microneedling to oral DOX improves clinical outcomes in patients with rosacea.</p><p><strong>Materials and methods: </strong>This retrospective comparative cohort study included 160 patients with clinically confirmed rosacea. Patients received either 12 weeks of oral DOX monotherapy at 100 mg/day (control group, <i>n</i> = 80) or the same DOX regimen combined with three monthly microneedling sessions (intervention group, <i>n</i> = 80). The primary endpoint was the treatment success rate for facial erythema at week 12. Secondary outcomes included improvement in inflammatory papulopustular lesions, flushing, capillary dilation, swelling, burning sensations, quality of life, 6-month erythema relapse rate, and safety.</p><p><strong>Results: </strong>At week 12, the intervention group showed a significantly higher treatment success rate for facial erythema than the control group (57.5% vs. 25.0%, <i>p</i> < 0.001). Improvement in inflammatory papulopustular lesions was substantial in both groups but did not differ significantly between them (75.0% vs. 70.0%, <i>p</i> = 0.478). Compared with DOX monotherapy, combination therapy produced significantly greater improvements in flushing, capillary dilation, swelling, burning sensations, and overall quality of life (all <i>p</i> < 0.01). The 6-month erythema relapse rate was also markedly lower in the intervention group than in the control group (20.0% vs. 68.4%, <i>p</i> < 0.001). No severe adverse events were observed.</p><p><strong>Conclusions: </strong>Adding microneedling to oral DOX was associated with greater improvement in vascular and neurosensory manifestations of rosacea, particularly facial erythema, flushing, and burning sensations. The combination approach also reduced erythema relapse at 6 months and was well tolerated.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2665538"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence-based recommendations for the treatment of recurrent aphthous stomatitis: insights from an umbrella review.","authors":"Nader A Al-Aizari, Hashem M Al-Shamiri, Bayan K AlShehri, Khalid S Alhomood, Saeed R Alzahrani, Waad R Abuhasna, Sadeq Ali Al-Maweri","doi":"10.1080/09546634.2026.2622245","DOIUrl":"10.1080/09546634.2026.2622245","url":null,"abstract":"<p><strong>Objective: </strong>To compare the effectiveness and safety of pharmacological, physical, and complementary interventions for recurrent aphthous stomatitis (RAS) across clinically relevant outcomes.</p><p><strong>Methods: </strong>This umbrella review was conducted according to PRISMA and Cochrane guidance and registered in PROSPERO (CRD42024594292). PubMed, Scopus, and the Cochrane Library were searched through August 2025. Eligible studies were systematic reviews, meta-analyses, or network meta-analyses evaluating treatments for RAS. Methodological quality was assessed using AMSTAR 2, and overlap of primary studies was quantified using the corrected covered area.</p><p><strong>Results: </strong>A total of 41 reviews were included. Topical corticosteroids and low-level laser therapy consistently reduced pain and shortened healing time, although evidence for recurrence prevention was limited. Hyaluronic acid and herbal agents demonstrated favorable short-term efficacy with good safety profiles. Systemic agents such as colchicine and thalidomide showed benefit in severe or refractory RAS, but were constrained by the adverse effects and low-certainty evidence.</p><p><strong>Conclusion: </strong>Evidence supports topical corticosteroids, hyaluronic acid, and laser therapy for short-term symptom control in RAS, while systemic agents should be reserved for selected refractory cases.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2622245"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of adult vitiligo: approved topical JAK inhibitor and standard therapies.","authors":"Maria Elisabetta Greco, Francesca Feresin, Alberto di Caro, Francesca Paola Sasso, Ilaria Proietti, Carmen Cantisani, Antonio di Guardo, Luigi Angelo Fiorito, Nicola Perrotta, Giovanni Pellacani, Concetta Potenza, Steven Paul Nisticò, Annunziata Dattola","doi":"10.1080/09546634.2026.2627721","DOIUrl":"10.1080/09546634.2026.2627721","url":null,"abstract":"<p><strong>Introduction: </strong>Vitiligo is a chronic autoimmune depigmenting disorder. Ruxolitinib 1.5% cream is currently the only therapy specifically approved for its treatment. In addition, clinical guidelines recommend off label standard therapies, including topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), phototherapy (narrowband UVB or excimer devices), and selected off-label systemic regimens.</p><p><strong>Materials and methods: </strong>This review summarizes the scientific evidence on approved and guideline-recommended treatments for adult vitiligo, using a PRISMA-based approach. Only English-language articles published between 2000 and 2025 were included. Interventions comprised approved therapies and standard treatments recommended by guidelines. Outcomes evaluated were changes in Facial and Total Vitiligo Area Scoring Index (F-VASI/T-VASI), quality of life, and safety. Risk of bias was assessed using the Risk of Bias 2 (RoB 2) tool for randomized controlled trials (RCTs) and the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) for non-randomized studies.</p><p><strong>Results: </strong>Ruxolitinib cream demonstrated superior F-VASI responses compared with vehicles in phase II-III RCTs. Evidence supports the efficacy of potent or very potent TCS, TCI, and NB-UVB or targeted 308-nm devices in localized disease.</p><p><strong>Conclusion: </strong>Systemic regimens show benefits in selected clinical scenarios, although supporting evidence remains heterogeneous. Treatment selection should be individualized based on disease activity, extent, anatomical site, and patient preferences.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2627721"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146204551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"24-week real world outcomes of nemolizumab in patients with prurigo nodularis.","authors":"Yoshihito Mima, Masako Yamamoto, Ken Iozumi","doi":"10.1080/09546634.2026.2624225","DOIUrl":"10.1080/09546634.2026.2624225","url":null,"abstract":"<p><strong>Backgrounds: </strong>Prurigo nodularis (PN) is a chronic pruritic inflammatory disease associated with immune and neural dysregulation. Although nemolizumab has demonstrated efficacy in clinical trials, real-world post-marketing data remain limited.</p><p><strong>Objective: </strong>To evaluate the real-world efficacy, safety, and drug survival of nemolizumab in patients with PN.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed 38 patients with PN treated with nemolizumab at a single center. Peak Pruritus Numerical Rating Scale (PP-NRS) and Prurigo Nodularis Investigator's Global Assessment (PN-IGA) were assessed up to Week 24. Treatment-emergent adverse events (TEAEs) and drug survival were evaluated.</p><p><strong>Results: </strong>Mean PP-NRS rapidly improved from 8.1 at baseline to 1.8 at Week 8 and remained stable through Week 24 (<i>p</i> < 0.001). PN-IGA scores gradually improved from 3.1 to 1.4 by Week 24 (<i>p</i> < 0.01). At Week 24, ≥4-point PP-NRS improvement and PP-NRS 0/1 were achieved in 90.9% and 59.1% of patients, respectively, while PN-IGA 0/1 was achieved in 50.0%. Early PP-NRS improvement correlated with long-term outcomes. TEAEs occurred in 39.5%, mainly cutaneous reactions, and drug survival was significantly lower in patients with TEAEs.</p><p><strong>Conclusion: </strong>Nemolizumab provided rapid and sustained itch relief with gradual lesion improvement in real-world PN. Early pruritus response may predict long-term efficacy, while adverse events affect treatment persistence.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2624225"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146115535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Off-label treatment of atopic dermatitis and psoriasis.","authors":"Julia Sternicka-Rohde, Leszek Bieniaszewski, Roman J Nowicki, Dorota Purzycka-Bohdan","doi":"10.1080/09546634.2026.2617768","DOIUrl":"10.1080/09546634.2026.2617768","url":null,"abstract":"<p><strong>Objectives: </strong>Off-label prescribing is a common and often necessary practice in dermatology, as approved treatment options frequently fail to meet the diverse needs of patients. This is particularly relevant in the management of two prevalent inflammatory dermatoses - atopic dermatitis and psoriasis. Despite the widespread use of off-label therapies, their application often lacks formal guidance, highlighting the need for updated clinical recommendations and consideration of expanded drug indications.</p><p><strong>Methods: </strong>This retrospective study analyzed medical records of 5072 patients with atopic dermatitis and/or psoriasis who were treated in Northern Poland between 2014 and 2024.</p><p><strong>Results: </strong>It was found that 62.5% of patients with atopic dermatitis and 25.7% of patients with psoriasis received some form of off-label treatment. The frequency of off-label therapy demonstrated an inverse correlation with patient age. On average, individuals managed with a combination of on-label and off-label therapies achieved greater reductions in EASI, PASI, and DLQI scores compared to those treated exclusively according to SmPC guidelines, with the statistically significant difference for PASI reductions.</p><p><strong>Conclusions: </strong>Off-label treatment is widely used in the management of both atopic dermatitis and psoriasis. Real-world evidence plays a crucial role in guiding clinical practice and should be leveraged to support the more evidence-based implementation of off-label therapies.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2617768"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146128136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intralesional human papillomavirus vaccination for cutaneous verrucae: a systematic review and meta-analysis of therapeutic efficacy.","authors":"Charussri Leeyaphan, Sumanas Bunyaratavej, Pattriya Jirawattanadon, Woramate Bhorntarakcharoen, Pheerawat Chaichanamongkol, Sukrit Kanchanasurakit","doi":"10.1080/09546634.2026.2688574","DOIUrl":"https://doi.org/10.1080/09546634.2026.2688574","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the efficacy of intralesional human papillomavirus (HPV) vaccination in the management of cutaneous warts.</p><p><strong>Methods: </strong>A comprehensive search of PubMed, MEDLINE, Embase, Scopus, and ClinicalTrials.gov was conducted in accordance with a registered PROSPERO protocol (CRD420251170324). Chronic or persistent warts were defined as lesions lasting more than six months or showing inadequate response to conventional therapies. The primary outcome was complete wart clearance, and pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model.</p><p><strong>Results: </strong>Six studies were included. Intralesional HPV vaccination was associated with a significantly higher rate of complete clearance compared with intralesional normal saline (RR 18.54; 95% CI 6.59-52.18). Subgroup analyses demonstrated comparable efficacy between bivalent and quadrivalent vaccines. Reported adverse events were mild and localized.</p><p><strong>Conclusion: </strong>Intralesional HPV vaccination demonstrated significant therapeutic efficacy in the treatment of cutaneous warts and represents a promising immunotherapeutic option for patients with persistent or treatment-refractory disease.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2688574"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148348057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recalcitrant tinea infections due to <i>Trichophyton indotineae</i> in the United States (2025-2026): a retrospective case series identified by real-time PCR.","authors":"Aditya K Gupta, Tong Wang, Sara A Lincoln, Wayne L Bakotic","doi":"10.1080/09546634.2026.2663646","DOIUrl":"10.1080/09546634.2026.2663646","url":null,"abstract":"<p><p><i>Trichophyton indotineae</i> is an emerging dermatophytic pathogen causing severe infections that are frequently resistant to standard antifungals. Since 2015, this species has spread intercontinentally.</p><p><strong>Objectives: </strong>To highlight the clinical characteristics and challenges in managing <i>T. indotineae</i> infections in the United States and to introduce the utility of rapid real-time PCR (qPCR) diagnosis.</p><p><strong>Methods: </strong>Records from a molecular diagnostics laboratory (Bako Diagnostics, GA, USA) were retrospectively reviewed for <i>T. indotineae</i> detections between May 2025 and January 2026. Cases were identified using a novel single-plex qPCR assay and confirmed by sequencing of the internal transcribed spacer region. The squalene epoxidase gene (<i>SQLE</i>) was sequenced to assess terbinafine resistance. A survey was distributed to treating physicians to collect information on recent international travel, household transmission, clinical features, immunosuppressive medications or conditions, and treatment history.</p><p><strong>Results and conclusions: </strong>All patients (median age: 54; 3 males and 2 females) reported recent travel to India or Nepal, except one, who was the spouse of a patient who had traveled to India. Two different <i>SQLE</i> substitutions were detected, F397L (<i>N</i> = 2) and L393F (<i>N</i> = 1), which are common among terbinafine-resistant <i>T. indotineae</i> isolates found globally. Potential gaps in clinical management - attributed to treatment initiation prior to confirmatory diagnosis of <i>T. indotineae</i> - were identified. These gaps include the use of topical corticosteroids, lack of itraconazole use (100-200 mg/day for 6-8 weeks or longer) as first-line treatment, and prescribing fixed, short treatment durations. In <i>T. indotineae</i> cases, these practices may increase the risk of disease recurrence and domestic spread. Current clinical recommendations are summarized herein, highlighting the utility of this novel qPCR assay for real-time treatment decision-making.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2663646"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe diffused glans penis venous malformation: successful management with 'fractional' Long-pulsed Nd: YAG laser therapy.","authors":"Xuan Jiang, Hongyuan Liu, Xi Yang, Gang Ma, Xiaoxi Lin, Li Hu, Hui Chen","doi":"10.1080/09546634.2026.2619292","DOIUrl":"10.1080/09546634.2026.2619292","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the efficacy and safety of 'fractional' long-pulsed Nd:YAG (FLP-Nd:YAG) for the treatment of severe diffused glans penis venous malformations (GPVM).</p><p><strong>Methods: </strong>Thirteen patients (Age 1.2-29 years) with diffused GPVM were enrolled in this study from August 2013 to January 2025. Twelve patients except one young male with erectile dysfunction underwent FLP-Nd:YAG laser treatment (there were intervals between circular spots). Outcome was graded using a five-point scale, and complications were documented after each session.</p><p><strong>Results: </strong>Ten patients reached a 'nearly cured' status, and two patients achieved an 'excellent' outcome. The mean number of sessions was 3.2 (range 2 ∼ 5). Symptoms were significantly alleviated following treatment. The minor complications were blister formation or thin crusting (<i>n</i> = 4), temporary hyperpigmentation (<i>n</i> = 5), superficial scars (<i>n</i> = 2), and mild hypesthesia (<i>n</i> = 1). Major complications included localized tissue depression (<i>n</i> = 1) and long-term fibrous nodules (<i>n</i> = 1). All patients were followed up for 4 to 11 months. Mild recurrence was observed in three cases.</p><p><strong>Conclusion: </strong>FLP-Nd:YAG laser therapy achieved high lesion clearance rates with low incidence of major complications in severe diffused GPVMs. It offered rapid treatment with a noninvasive, bloodless procedure, making it especially suitable for pediatric patients.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2619292"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147273026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}